Chemoradiotherapy in Unresectable Esophageal Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
About this trial
This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
Eligibility criteria
Qualifiers
18~75 years
Pathologically or cytologically proven unresectable esophageal squamous cell carcinomas in patients staged as T3N1M0-1b and T4N0-1M0-1b(AJCC 6th TNM staging,M1b limited to clavicular or celiac lymph node metastasis)
Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences
ECOG PS score: 0~1
Disqualifiers
With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc
Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer
Existing active infection such as active tuberculosis and hepatitis
History of myocardial infarction within the past 6 months or history of ventricular arrhythmia
Trial design
Treatments tested in this trial
- Radiotherapy
- Albumin-Bound Paclitaxel
- Cisplatin
Treatment groups
105 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov